Medigene Secures Japanese Patent for Innovative T-Cell Receptor Technology

In a strategic move to secure their forward-looking cancer therapies, Medigene AG has received a significant patent grant from Japan. The biotechnology company, which specializes in immuno-oncological therapy for solid tumors, announced that the Japanese Patent Office has awarded it a technology patent for the inducible T-cell receptor (iM-TCR). This technology allows for the precise adjustment of the activity of T-cell receptor-modified therapies (TCR-T) after their application, thereby enhancing treatment efficacy and improving the safety profile for the patient. The CEO of Medigene, Selwyn Ho, expressed his pleasure at this progress and highlighted the importance of iM-TCR to the company's comprehensive portfolio. He stressed the innovative strength of the technology and its contribution to the company's end-to-end platform, which already includes several proprietary enhancement technologies. The iM-TCR is a key element in the design of highly specific, safe, and customized therapeutic approaches targeted at the individual characteristics of solid tumors. Medigene's iM-TCR technology offers the possibility of effectively dampening excessive immune system activity and inflammatory responses through targeted modification of T-cell receptors. This approach has the potential to reduce undesired side effects of therapy, particularly in the treatment of tumors in sensitive organ areas such as the brain and liver. In addition to the current patent grant, the company is on the verge of receiving regulatory approval for its leading TCR-T program MDG1015, thus continuing to rely on its broad spectrum of proprietary technologies for T-cell receptor optimization – a strong foundation for the development of novel immunotherapies. By combining various methods, from TCR generation to product enhancement, as well as through international partnerships with players such as BioNTech and 2seventy bio, Medigene reinforces its position as a pioneer in the field of targeted cancer therapies. Medigene thus once again proves that its investments in research and development are based on a solid foundation of existing and future patent rights, which should offer confident prospects for both patients and shareholders.